Improving Community-Based Care for Adolescents with ADHD: a Randomized Controlled Trial of Artificial Intelligence-Assisted Fidelity Supports.

Prev SciDec 24, 2025 (epub)
Clinical ResearchPsychiatryOpen access

Margaret H Sibley, Leonard Bickman, David Atkins et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated whether AI-assisted implementation supports improved delivery of Supporting Teens’ Autonomy Daily (STAND), a cognitive-behavioral treatment blended with Motivational Interviewing, in community care. The study included 51 adolescents with ADHD treated by 23 therapists across three community mental health agencies. Compared with standard supports, the AI-assisted package was associated with more efficient treatment delivery and fewer appointments attended by adolescents. However, MI quality declined significantly over time in the AI-assisted group relative to standard support. Focus groups suggested therapists may have prioritized efficiency over relational aspects of therapy.

Key findings

  • AI-assisted supports were associated with more efficient treatment delivery and fewer appointments attended by adolescents.
  • MI quality declined significantly over time in the AI-assisted group compared with the standard-support group.
  • Therapists in focus groups linked the AI-assisted package with a task-oriented mindset and prioritization of efficiency over relational aspects of therapy.

Why it matters

Implementation tools may help community clinics deliver evidence-based treatment more efficiently, but efficiency alone may not preserve important therapeutic qualities. The reported decline in MI quality highlights the need to assess both delivery processes and patient outcomes when introducing AI-assisted supports into routine mental health care.

What to keep in mind

The trial involved 51 adolescents, 23 therapists, and three community mental health agencies. The abstract does not report mental health outcomes or cost savings; the authors call for a larger trial to examine these.

Source

Published in Prev Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.